Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20250711018
- Term of Validity
- 11 July 2025 - 11 July 2026
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- UK SME specialises in novel wearable neuromonitoring technology offers a configurable, self-applied electroencephalography system and support service for remote, home-based research applications. This is the world’s smallest medical grade patch format EEG, designed for high-quality, longitudinal data collection. Seeking commercial agreements with technical assistance with academic institutions, contract research organisations and commercial R&D departments. Also open to investment agreements.
- Full Description
-
This UK SME develops novel biosensor and AI platforms to make high-quality neuromonitoring accessible and scalable. With expertise in medical-grade device development, the company collaborates extensively with leading academics, clinicians, and NHS trusts on grant-funded research projects in areas including epilepsy, sleep, neonatal care, and dystonia.
The core technology is a discreet, wearable electroencephalography (EEG) system designed for ease of use, enabling research participants to self-apply the device without clinical supervision. This facilitates high-quality data collection in natural home environments over extended periods, supporting longitudinal studies.
The company offers a flexible service model tailored to research needs. This includes shipping pre-configured device kits directly to study participants, managing return logistics, and processing data. This approach reduces administrative burdens on research teams and eliminates the need for in-person EEG appointments. Alternatively, partners may opt for a traditional ownership model with direct device management. Data delivery options range from raw signals to various levels of automated processing, adaptable to the partner’s research protocols.
Fundamentally, the company's mission is aligned with key UN Sustainable Development Goals. By making advanced neurological monitoring accessible and affordable, the technology directly supports Goal 3 (Good Health and Well-being). The innovative nature of the platform and scalable service model contribute to Goal 9 (Industry, Innovation and Infrastructure) by enhancing research capabilities. Furthermore, by removing geographical and economic barriers, the service actively works towards Goal 10 (Reduced Inequalities), bringing essential diagnostic tools to underserved populations.
The company seeks commercial agreements with technical assistance, working with research academic institutions, contract research organisations (CROs), and commercial R&D departments. It is also open to investment agreements to support business growth and market expansion. - Advantages and Innovations
-
This technology offer addresses the key limitations of traditional EEG, which is often expensive, requires specialist technicians, and is confined to a clinical setting.
• Accessibility and scalability: The self-applied, home-based model enables large-scale, longitudinal studies that are impractical or cost-prohibitive with conventional EEG systems. This is ideal for research involving large or geographically dispersed populations.
• High-throughput in lab assessments: Beyond remote use, the system's intuitive and quick-application design is ideal for high-volume lab environments. It significantly reduces the setup time per participant, enabling research teams to manage larger cohorts and increase the throughput of in-person assessments with minimal operational overhead and easy data access.
• Patient-centric design: The system is designed to be self-applied by participants, removing the barrier of travel and the need for a technician to be present. This improves the participant experience and can increase recruitment and retention in studies.
• Cost-effectiveness: The low-cost hardware and efficient drop-ship service model significantly reduce the per-participant cost of neurological research, allowing for more extensive studies within a given budget.
• High-quality data: Despite its simplicity and low cost, the system provides high-quality, research-grade EEG data that is been validated in multiple ongoing studies with UK universities and NHS trusts.
• Research configurability: The platform is highly configurable to meet specific research needs, with options for bespoke electrode design and placement, custom device casings, and tailored data collection protocols. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 10: Reduced Inequality
- Goal 9: Industry, Innovation and Infrastructure
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
Partner Sought
- Expected Role of a Partner
-
This profile seeks partners to collaborate on innovative research projects that require remote, continuous EEG monitoring.
• Type of partner sought:
Academic research institutions, universities, Contract Research Organisations (CROs), and R&D departments within pharmaceutical or med-tech companies. The company also welcomes contact from investors interested in the med-tech and digital health sectors.
• Target sector:
Healthcare, Neuroscience, Clinical Trials, Digital Health, and Psychology.
• Role/tasks to be performed by the partner:
The ideal partner will be conducting research requiring longitudinal or large-scale EEG data collection. The partner would procure the monitoring service for use in their funded research projects, clinical trials, or R&D programs. The partner would typically be responsible for the overall study design, ethics approval, participant recruitment, and final data analysis and interpretation. The UK SME will provide the monitoring technology, full logistical support (including direct-to-participant shipping), and technical assistance under a service agreement. The desired outcome is a collaboration that leverages this unique remote monitoring system to generate novel insights and high-impact research publications. For investors, the opportunity is to participate in a SEED funding round to scale the company's operations and accelerate market entry. - Type and Size of Partner
- SME <=10
- University
- R&D Institution
- Other
- SME 50 - 249
- Big company
- SME 11-49
- Type of partnership
- Commercial agreement with technical assistance
- Investment agreement
Dissemination
- Technology keywords
- 01003003 - Artificial Intelligence (AI)
- 06001005 - Diagnostics, Diagnosis
- 06001002 - Clinical Research, Trials
- 06001014 - Neurology, Brain Research
- Market keywords
- 05001007 - Other diagnostic
- 02007012 - Medical/health software
- 05004005 - Diagnostic equipment
- 05001001 - Diagnostic services
- Sector Groups Involved
- Health
- Digital
- Targeted countries
- All countries